|
Characteristics
|
Probiotic
|
Placebo
|
|---|
|
n
| |
n
| |
|---|
|
Age, mother, yrs mean (SD)
|
129
|
30.5 (3.9)
|
130
|
30.3 (4.1)
|
|
Sex (male), child, n (%)
|
129
|
67 (51.9)
|
130
|
53 (40.8)
|
|
Siblings, n (%)
|
129
|
60 (46.5)
|
130
|
54 (41.5)
|
|
Atopy in family, n (%)
|
129
|
91 (70.5)
|
130
|
96 (73.9)
|
|
Maternal atopy, n (%)
|
129
|
58 (45.0)
|
129
|
68 (52.7)
|
|
Maternal smokinga, n (%)
|
129
|
9 (7.0)
|
130
|
11 (8.5)
|
|
Compliantb, n(%)
|
125
|
113 (90.4)
|
128
|
115 (89.8)
|
|
Allergy related disease at 2 years
|
n
|
n (%)
|
n
|
n (%)
|
p-valuec
|
|---|
|
Atopic dermatitis, n (%)
|
129
|
29 (22.5)
|
130
|
45 (34.6)
|
0.031
|
|
Asthma, n (%)
|
129
|
7 (5.4)
|
130
|
12 (9.2)
|
0.240
|
|
Allergic rhinoconjunctivits, n (%)
|
125
|
1 (0.8)
|
129
|
0 (0.0)
|
0.492
|
|
Sensitisationd, n (%)
|
122
|
19 (15.6)
|
124
|
15 (12.1)
|
0.429
|
-
aMaternal smoking reported during pregnancy, 6 weeks or 12 months postpartum; b Compliance with the study protocol was defined by consumption of the study milk on at least 50 % of days from 36 weeks gestation to 12 postpartum, no consumption of other products with probiotics and at least partial breastfeeding until 3 months postpartum; c p-value calculated using χ2-test, except for allergic rhinoconjunctivits where a Fisher’s exact p value is reported; d Allergic sensitisation defined as positive skin prick test (wheal ≥ 3 mm) and or positive sIgE (≥ 0.35 kUL−1)
